Basic Information
The Brazilian Journal of Otorhinolaryngology aims to provide timely information for physicians and scientists focused on otorhinolaryngology and head and neck disorders, including contemporary, ethical, clinically relevant information in:
The journal is the official peer-reviewed open access scientific publication of the Brazilian Association of Otorhinolaryngology and Cervicofacial Surgery (ABORL-CCF). All articles will be published under the CC-BY license (Creative Commons Attribution 4.0 International) with copyright owned by the ABORL-CCF. Please note that articles submitted as of May 1, 2022, which are accepted for publication will be subject to a fee (Article Publishing Charge, APC) payment by the author or research funder to cover the costs associated with publication. |
Indexation Source
|
Intellectual Property
All articles will be published under the CC BY (Creative Commons Attribution 4.0 International). Open Access funded by Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. |
Editor-in-Chief
|
Co-Editors
|
Associate Editors
|
Reviewers
|
ABORL-CCF Executive board 2021
PRESIDENT
1st VICE-PRESIDENT
2nd VICE-PRESIDENT
EXECUTIVE DIRECTOR – GENERAL SECRETARY
EXECUTIVE DIRECTOR – ADJUNCT SECRETARY
EXECUTIVE DIRECTOR – GENERAL TREASURER
EXECUTIVE DIRECTOR – ADJUNCT TREASURER
Advisors: |
Standing Commitees
EVENTOS E CURSOS Presidente: Arthur Menino Castilho COMUNICAÇÃO Presidente: Alexandre Beraldo Ordones EDUCAÇÃO MÉDICA CONTINUADA Presidente: Andreia Ardevino de Oliveira ÉTICA E DISCIPLINA Presidente: Ricardo Ferreira Bento RESIDÊNCIA E TREINAMENTO Presidente: Fernando Kaoru Yonamine
TÍTULO DE ESPECIALISTA Presidente: Ana Cristina Kfouri Camargo PLANEJAMENTO ESTRATÉGICO Presidente: Jose Eduardo Lutaif Dolci |
Guide for authors
The BJORL is an open-access peer-reviewed journal dedicated to the advancement of patient care in Otorhinolaryngology - Head and Neck Surgery. The BJORL publishes original articles relating to both the clinical and basic science aspects of Otorhinolaryngology. The Journal reserves the right to exclusive publication of all accepted manuscripts. Manuscripts previously published or under review by another publication will not be considered by any chance. Once accepted for review, the manuscript must not be submitted elsewhere. Unethical publishing, such as plagiarism, undisclosed conflicts of interest, inappropriate authorship, and duplicate publication are forbidden. This includes publication in a non-otorhinolaryngology journal or in another language. In case of doubt, disclosure is essential, and the Editor is available for consultation. Transfer of copyright to BJORL is a prerequisite of publication. All authors must sign a Copyright Transfer Agreement form. This form must be uploaded in the submission files. Authors must disclose any financial relationship(s) at the time of submission. Information that could be perceived as potential conflict(s) of interest, such as grants or funding, employment, affiliations, patents, inventions, honoraria, consultancies, royalties, stock options/ownership, or expert testimony, must be stated. The BJORL welcomes manuscripts related to general otolaryngology; head and neck surgery; respiratory sleep disorders; allergy/rhinology; otology/neurotology; laryngology/bronchoesophagology; pediatric otolaryngology; cranio-facial surgery; skull base surgery; head and neck oncology; phoniatrics; upper airway related diseases; and facial plastics and reconstructive surgery. Please note that articles submitted as of May 1, 2022, which are accepted for publication will be subject to a fee (Article Publishing Charge, APC) payment by the author or research funder to cover the costs associated with publication. All articles must be submitted in English. More information, including the APC, can be found at: https://www.elsevier.com/journals/brazilian-journal-of-otorhinolaryngology/1808-8694/open-access-journal |
Types of paper
The Brazilian Journal of Otorhinolaryngology publishes Original Reports, Contemporary Reviews, Systematic and Evidence-Based Reviews, Letters to the Editor, and Invited Articles and Reviews. Topics of interest include all subjects that relate to the practice of medicine and the betterment of public health worldwide. Original Reports
Original articles are concise (1) reports of clinical data, (2) reports of basic science data, or (3) meta- analyses studies, that represent advanced information, and should present data that have not yet been published.
Word count: 3,000 words (max), excluding abstract and references. Number the pages of the manuscript consecutively, beginning with the Title Page as page 1. Please use a spell-checker in addition to careful editing of the manuscript before submission. Authors should not add line numbering as this is automatically added by the submission system. Original Reports should be formatted as follows:
Highlights Contemporary Reviews
This type of paper should address a new and/or rapidly evolving topic including diagnostic or therapeutic advances, or technological innovations. Whenever possible, a Systematic Literature Review with or without a Meta-Analysis is preferred over a Contemporary Review.
Word count: 3,000 words (max), excluding abstract and references. Number the pages of the manuscript consecutively, beginning with the Title Page as page 1. Please use a spell-checker in addition to careful editing of the manuscript before submission. Authors should not add line numbering as this is automatically added by the submission system. Contemporary Reviews should be formatted as follows:
Highlights Systematic and Evidence-Based Reviews Submissions of Systematic Reviews are highly encouraged by the BJORL editors. They address a specific question or issue that is relevant for clinical practice and provide an evidence-based, balanced, patient-oriented review on a focused topic. Reviews should include the clinical question or issue and its importance for general medical practice, specialty practice, or public health; description of how the relevant evidence was identified, assessed for quality, and selected for inclusion; synthesis of the available evidence such that the best-quality evidence (e.g., well-conducted clinical trials, meta- analyses, and prospective cohort studies) should receive the greatest emphasis; and discussion of controversial aspects and unresolved issues. A structured abstract is required. Authors are encouraged to adhere to study standards, for example the PRISMA guideline for systematic reviews.
Word count: 4,000 words (max), excluding abstract and references. Number the pages of the manuscript consecutively, beginning with the Title Page as page 1. Please use a spell-checker in addition to careful editing of the manuscript before submission. Authors should not add line numbering as this is automatically added by the submission system. Systematic and Evidence-Based Reviews should be formatted as follows:
Highlights Letters to the Editor
It should comment on previously published research in which significant scientific controversy exists. A Letter to the Editor deemed appropriate for publication will be submitted to the author(s) of the published article so they can provide comments.
Word count: 400 words (max). Letters in Reply Replies by authors should not exceed 500 words of text and 5 references. They should have no more than 3 authors. Invited Articles and Reviews The Journal may, at times, invite original research and reviews on specific topics. These topics would require broad coverage or unusual publication treatment. These invited works will be subject to standard peer-review. If accepted, the Editor-in-Chief of the Journal may choose to publish the article in print and online, or online only. Editorials Editorials provide a forum for interpretive, analytical, or reflective opinions related to manuscripts in the BJORL or statements about clinical, scientific, or socioeconomic issues. The invitation-only Editorial should be objective and dispassionate but is likely to provide alternative points of view and some bias. Editorials should not exceed 1,200 words with no more than 5 references. Editorials do not have an Abstract.
Funding Authors should list all funding sources in the Acknowledgments section. Authors are responsible for the accuracy of their funder designation. If in doubt, please check the Open Funder Registry for the correct nomenclature: https://www.crossref.org/services/funder-registry/ Ethics in publishing Please see our information pages on Ethics in publishing and Ethical guidelines for journal publication. Informed consent and patient details
Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author but copies should not be provided to the journal. Only if specifically requested by the journal in exceptional circumstances (for example if a legal issue arises) the author must provide copies of the consents or evidence that such consents have been obtained. For more information, please review the Elsevier Policy on the Use of Images or Personal Information of Patients or other Individuals. Unless you have written permission from the patient (or, where applicable, the next of kin), the personal details of any patient included in any part of the article and in any supplementary materials (including all illustrations and videos) must be removed before submission. The authors should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans https://www.wma.net/policies-post/wma-international-code-of-medical-ethics/
Personal communications and unpublished data
Species Names
Genetic Nomenclature Proteins sequence data should be submitted to either of the following repositories:
Structural Data
Previous release of information Conflict of interest All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places: 1. A summary declaration of interest statement in the title page file (if double anonymized) or the manuscript file (if single anonymized). If there are no interests to declare then please state this: 'Declarations of interest: none'. This summary statement will be ultimately published if the article is accepted. 2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the journal's official records. It is important for potential interests to be declared in both places and that the information matches. More information.
Corresponding author The corresponding author will be the representative of all coauthors as the primary correspondent with the editorial office during the submission and review process. If the manuscript is accepted, the corresponding author will review an edited typescript and proof, make decisions regarding release of information in the manuscript to the news media, federal agencies, or both, and will be identified as the corresponding author in the published article. The corresponding author is responsible for ensuring that the reported conflict of interest disclosures are accurate, up-to-date, and consistent with the information provided for each author. Submission declaration and verification
Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright- holder. To verify originality, your article may be checked by the originality detection service Crossref Similarity Check. Use of inclusive language Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive. Authorship The list of authors should accurately illustrate who contributed to the work and how. All those listed as authors should qualify for authorship according to the following criteria in accordance with ICMJE standards:
The number of authors should not exceed to seven, otherwise must be justified and the editorial board will evaluate case by case. ORCID As part of the journal's commitment to supporting authors at every step of the publishing process the journal requires the submitting author (only) to provide an ORCID iD when submitting a manuscript. If you don't have an ORCID ID, it can be registered at https://orcid.org/register.
Changes to authorship
Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Protocols
Authors of manuscripts reporting clinical trials are encouraged to submit trial protocols (including the complete statistical analysis plan) along with their manuscripts. Copyright
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' to assign to the society the copyright in the manuscript and any tables, illustrations or other material submitted for publication as part of the manuscript (the "Article") in all forms and media (whether now known or later developed), throughout the world, in all languages, for the full term of copyright, effective when the Article is accepted for publication. Besides, the journal also request a signed Copyright Statement. A template is available at: https://static.elsevier.es/miscelanea/authors-agreement-copyright-transference-2021.docx. Role of the funding source You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated. Open access Please visit our Open Access page for more information. Embargo policy All information regarding the content and publication date of accepted manuscripts is strictly confidential. Unauthorized prepublication release of accepted manuscripts may result in rescinding the acceptance and rejecting the paper. This policy applies to all categories of articles, including Original Investigations, Reviews, Editorials, Viewpoints, Letters, etc. Information contained in or about accepted articles cannot appear in print, audio, video, or digital form or be released by the news media until 3 pm central time on the third Thursday of the month (or other specified embargo release date for the cases in which articles are released early). Unauthorized use
Published manuscripts become the permanent property of the Elsevier and may not be published elsewhere without written permission. Unauthorized use of the Elsevier name, logo, or any content for commercial purposes or to promote commercial goods and services (in any format, including print, video, audio, and digital) is not permitted by the Elsevier. Submission
Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail. All submitted manuscripts are reviewed initially by a Brazilian Journal of Otorhinolaryngology editor. Manuscripts are evaluated according to the following criteria: material is original and timely, writing is clear, study methods are appropriate, data are valid, conclusions are reasonable and supported by the data, and information is important. From these basic criteria, the editors assess a paper’s eligibility for publication. Manuscripts with insufficient priority for publication are rejected promptly. |
Preparation
Double anonymized review
This journal uses double anonymized review, which means the identities of the authors are concealed from the reviewers, and vice versa. More information is available on our website. To facilitate this, please include the following separately: The complete paper must not exceed 25 pages of A4 (21 cm x 29.7 cm) size paper, written in size 12 Times New ptype, double spacing between the lines. If the reviewer considers necessary, he/ she may suggest the author to suppress figures or tables or even to condense the text. Article structure
Introduction Essential title page information Title Page
Highlights Highlights are mandatory for original and review articles. They consist of a short collection of bullet points that capture the novel results of your research as well as new methods that were used during the study (if any). Please have a look at the examples here: example Highlights. Highlights should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). Abstract A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions, with no more than 300 words. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, references must be avoided. Also, non-standard or uncommon abbreviations must be avoided. For original and review articles, the abstract must be structured in: Objective(s), Methods, Results, and Conclusion(s). Keywords Three to five keywords must be listed, and they can be found on MeSH (Medical Subject Headings, https://www.nlm.nih.gov/mesh/meshhome.html). Abbreviations
Do not use abbreviations in the title or abstract and limit their use in the text. Expand all abbreviations at first mention in the text. Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa]. It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding. If no funding has been provided for the research, please include the following sentence: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Nomenclature and Units Units of measure Laboratory values are expressed using conventional units of measure, with relevant Système International (SI) conversion factors expressed secondarily (in parentheses) only at first mention. Articles that contain numerous conversion factors may list them together in a paragraph at the end of the “Methods” section. In tables and figures, a conversion factor to SI should be presented in the footnote or legend. The metric system is preferred for the expression of length, area, mass, and volume. For more details, see the Units of Measure conversion table on the website for the AMA Manual of Style. Names of drugs, devices, and other products Use nonproprietary names of drugs, devices, and other products, unless the specific trade name of a drug is essential to the discussion. Gene names, symbols, and accession numbers
Authors describing genes or related structures in a manuscript should include the names and official symbols provided by the US National Center for Biotechnology Information (NCBI) or the HUGO Gene Nomenclature Committee. Before submission of a research manuscript reporting on large genomic data sets (eg, protein or DNA sequences), the data sets should be deposited in a publicly available database, such as NCBI’s GenBank, and a complete accession number (and version number if appropriate) must be provided in the “Methods” section of the manuscript.
A detailed guide on electronic artwork is available. You are urged to visit this site; some excerpts from the detailed information are given here.
Formats Please do not:
Color artwork
Illustration services All figure must be placed after Tables in separate pages. Tables Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells. References
Citation in text
A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article. An example of a citation using DOI for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. Journal of Geophysical Research, https://doi.org/10.1029/2001JB000884. Please note the format of such citations should be in the same style as all other references in the paper.
Reference style
Online journals Friedman SA. Preeclampsia: a review of the role of prostaglandins. Obstet Gynecol [serial online]. January 1988;71:22-37. Available from: BRS Information Technologies, McLean, VA. Accessed December 15, 1990. Book chapter Todd VR. Visual information analysis: frame of reference for visual perception. In: Kramer P, Hinojosa J, eds. Frames of Reference for Pediatric Occupational Therapy. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:205-56. Entire book Webster NR, Galley HF. Anaesthesia Science. Oxford, UK: Blackwell Publishing, Ltd.; 2006. Database CANCERNET-PDQ [database online]. Bethesda, MD: National Cancer Institute; 1996. Updated March 29, 1996. Software Epi Info [computer program]. Version 6. Atlanta, GA: Centers for Disease Control and Prevention; 1994. Web sites Gostin LO. Drug use and HIV/AIDS [JAMA HIV/AIDS Web site]. June 1, 1996. Available at: http://www.ama-assn.org/special/hiv/ethics. Accessed June 26, 2012. Web references Please keep a print copy of any reference to web-only information. If the URL changes or disappears, interested readers may contact the corresponding author for a copy of the information. Authors are responsible for the accuracy and completeness of their references and for correct text citation.
Research data This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project. Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the research data page.
Data linking There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the database linking page. For supported data repositories a repository banner will automatically appear next to your published article on ScienceDirect.
In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN). For more information, visit the Mendeley Data for journals page.
Submission Checklist The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item. Ensure that the following items are present: One author has been designated as the corresponding author with contact details:
All necessary files have been uploaded, and contain:
For any further information please visit our customer support site at https://service.elsevier.com.
Highlights should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point).
AFTER ACCEPTANCE Proofs
One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author (if we do not have an e-mail address then paper proofs will be sent by post) or a link will be provided in the e- mail so that authors can download the files themselves. To ensure a fast publication process of the article, we kindly ask authors to provide us with their proof corrections within two days. Elsevier now provides authors with PDF proofs which can be annotated; for this you will need to download the free Adobe Reader, version 9 (or higher). Instructions on how to annotate PDF files will accompany the proofs (also given online). The exact system requirements are given at the Adobe site. AUTHOR INQUIRIES
Visit the Elsevier Support Center to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch. |